Angivent MR Tablet (Modified Release)

Brand Name: Angivent MR
Generic: Trimetazidine Dihydrochloride
Weight: 35 mg
Type: Tablet (Modified Release)
Therapeutic Class: Other Anti-anginal & Anti-ischaemic drugs
Manufacturer: Square Pharmaceuticals Ltd.
Price: 7.00
Last Updated: 2020-11-21 18:15:00

Angivent MR Tablet (Modified Release) Uses

Angivent MR Tablet (Modified Release) contains Trimetazidine Dihydrochloride. Angivent MR uses:

Long-term treatment of Ischaemic heart disease (angina pectoris, sequelae of infarction).

Angivent MR Tablet (Modified Release) Doses

Angivent MR Tablet (Modified Release) contains Trimetazidine Dihydrochloride 35 mg. Angivent MR doses:

One 20 mg tablet thrice daily after meals. No dosage adjustments are required in patients with impaired renal and hepatic function.

One 35 mg modified release tablet twice daily at mealtimes in the morning and evening.

 

Side Effects

Trimetazidine is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.

Introduction

Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity, which results in a reduction in fatty acid oxidation and a stimulation of glucose oxidation. High fatty acid oxidation rates are detrimental during ischemia due to an inhibition of glucose oxidation leading to uncoupling of glycolysis and an increase in proton production, which has the potential to accelerate sodium and calcium overload in the heart. This leads to an exacerbation of ischemic injury and decreased cardiac efficiency during reperfusion.

Angivent MR Precaution

 

Interaction

No drug interactions have so far been reported. In particular, no interactions of Trimetazidine with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis have been reported.

Pregnancy Lactation use

Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.

Nursing Mothers: There is no information on the secretion of Trimetazidine into breast milk. However, breast feeding should be discontinued if the use of Trimetazidine is considered essential.

Contraindication

Hypersensitivity to Trimetazidine Dihydrochloride.

Special Warning

 

Acute Overdose

 

Interaction with other Medicine

 

Storage Condition

Store in a cool and dry place, protect from light and moisture. Keep out of the reach of children.

Angivent MR Tablet (Modified Release) price in Bangladesh 7.00